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Comparison of Platinum-Based Chemotherapy in Patients
Older and Younger than 70 Years
An Analysis of Southwest Oncology Group Trials 9308 and 9509
Elizabeth M. Blanchard, MD,* James Moon, MS,† Paul J. Hesketh, MD,‡ Karen Kelly, MD,§
Antoinette J. Wozniak, MD, John Crowley, PhD,† and David Gandara, MD#
Purpose: This retrospective analysis sought to investigate the
safety, feasibility, and outcomes of platinum doublet therapy in
patients aged 70 years or older with advanced non-small cell lung
cancer compared with patients younger than 70 years who partici-
pated in two randomized phase III trials conducted by the Southwest
Oncology Group.
Patients and Methods: Outcomes and toxicity data from fit patients
with stage IIIB or stage IV non-small cell lung cancer treated with
cisplatin/vinorelbine and carboplatin/paclitaxel were pooled from
Southwest Oncology Group trials 9308 (S9308) and 9509 (S9509)
and compared with respect to age.
Results: A total of 616 patients were available for efficacy analyses,
of which 122 (20%) were aged 70 years or older. The median
progression-free survival was 4 months in both age groups (p 
0.71), and response rates were similar. Overall survival was signif-
icantly higher in the younger patient cohort (median 9 months versus
7 months, p  0.04). Individual parameters of toxicity were similar
in both age groups.
Conclusion: Although patients aged 70 years or older derived initial
benefit from platinum-based therapy, survival was better in younger
patients. Additional studies in this growing patient population are
needed to develop treatment strategies that minimize toxicity and
increase efficacy.
Key Words: NSCLC (non-small cell lung cancer), elderly, plati-
num-based therapy.
(J Thorac Oncol. 2011;6: 115–120)
Advanced non-small cell lung cancer (NSCLC) remains achallenging disease. Recent demographic trends reveal
that NSCLC is increasingly becoming a disease of older
patients. The median age of newly diagnosed patients in the
United States is now 70 years.1 It is estimated that in the year
2050, more than 400,000 new patients with lung cancer will
be diagnosed in the United States, which is more than double
the number of patients diagnosed in the year 2000.2 Not only
will a significant proportion of patients be older than 70 years
but also 15% will be aged 85 years or older. This trend sends
an urgent message to identify treatments that are both effec-
tive and well tolerated by older patients, where the balance
between efficacy and toxicity is often more delicate.
Chemotherapy has been shown to both prolong survival
and improve quality of life in patients with metastatic NSCLC.3,4
Combination chemotherapy, specifically platinum-based dou-
blet therapy remains the cornerstone of treatment for fit patients
with advanced NSCLC.5,6 Many clinicians have concerns about
aggressive treatment for elderly patients, and as a result, the use
of chemotherapy in patients with advanced lung cancer de-
creases with age, and a substantial proportion of older patients
do not receive active therapy.7–9 Nevertheless, large series have
demonstrated that although comorbid illness or compromised
performance score can predict for poor outcomes for patients
with NSCLC treated with chemotherapy, patients with ad-
vanced age and a good performance status can derive a
similar degree of benefit from chemotherapy compared with
younger patients.10–13
Randomized trials for elderly patients have been lim-
ited to nonplatinum-based regimens. Single-agent chemother-
apy, specifically vinorelbine, has been shown to increase
survival and improve lung cancer-related symptoms in el-
derly patients compared with best supportive care.14 Never-
theless, a subsequent large randomized phase III trial15 in
elderly patients found no additional survival benefit with the
combination of gemcitabine and vinorelbine compared with
either agent alone. The benefit of combination chemotherapy,
specifically platinum-based chemotherapy is less clear, as no
large prospective randomized phase III trial testing platinum-
based therapy in an elderly specific trial has been fully
reported to date. Lilenbaum et al.16 prospectively analyzed
patients aged 70 years or older in a trial comparing carbo-
platin and paclitaxel to paclitaxel alone and found no differ-
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ence in survival between the younger and elderly patients for
either arm. Second-line chemotherapy, though, has been
shown to provide benefit for elderly patients with advanced
NSCLC with similar toxicity as younger patients.17
The literature suggests that toxicity is increased in older
patients treated with chemotherapy, particularly hematologic
toxicity, although data are conflicting. In a retrospective
analysis of elderly patients with advanced NSCLC who
participated in Eastern Cooperative Oncology Group (ECOG)
trials,18 more leucopenia was noted in patients older than 70
years, although rates of infection and thrombocytopenia were
not different in patients treated with either cisplatin and
etoposide or a combination of high- or low-dose paclitaxel
and cisplatin. In another retrospective series using two-,
three-, and four-drug cisplatin-based combinations, increased
myelotoxicity was seen in elderly patients being treated for
advanced NSCLC,19 but it is not clear whether this holds true
for modern platinum doublet therapy. A smaller retrospective
series of elderly patients treated with carboplatin and pacli-
taxel (CP) did not find any difference in hematologic or
nonhematologic toxicity between patients older or younger
than age 70 years.20 In addition, the small subset of patients
older than 70 years participating in ECOG 1594, which com-
pared platinum-based doublets in advanced NSCLC, found
equivalent toxicity and outcomes between patients younger than
70 years and those between 70 and 80 years.21
In an effort to determine the potential benefit, toxicity,
and feasibility of platinum-based combination chemotherapy
in elderly patients with advanced NSCLC, the Southwest
Oncology Group (SWOG) has undertaken an analysis of
S930822 and S9509,23 two phase III studies published previ-
ously on the use of platinum-based combination therapy in
advanced NSCLC. This retrospective analysis combines the
results and toxicity data from both studies and divides pa-
tients into two groups: patients younger than 70 years and
those aged 70 years or older who received combination
platinum-based therapy. The two cohorts were compared
with respect to baseline characteristics, number of chemo-
therapy cycles given, toxicity, response, and survival. Herein,
we describe the results of this analysis.
PATIENTS AND METHODS
Patients
Patients were recruited from SWOG-affiliated sites in
the United States. Eligibility criteria for S9308 and S9509
were similar and included patients with stage IV disease and
selected stage IIIB patients with either pleural effusions or
multiple ipsilateral lung nodules. All patients were required
to have histologically confirmed NSCLC with measurable or
assessable disease. Patients with brain metastases were ex-
cluded. Patients were required to have a performance status
of 0 or 1. Previous chemotherapy was an exclusion criterion,
but prior radiation and surgery were permitted. Adequate
organ function and hematologic parameters were mandated.
Both studies were approved by the institutional review board
at each participating site, and signed informed consent from
all patients was required.
In both studies, patients were stratified by lactate de-
hydrogenase, stage (IIIB or IV), disease status (measurable or
nonmeasurable), prior surgery or radiation, and histology
(squamous cell, large cell, adenocarcinoma, or unspecified).
Patients in S9509 were also stratified by weight loss (greater
or less than 5%).
Treatment Schedule
In S9308, patients were randomized to cisplatin alone
or cisplatin plus vinorelbine (CV). Cisplatin was given every
4 weeks at a dose of 100 mg/m2 on both arms. Patients in the
combination arm also received vinorelbine 25 mg/m2 weekly.
Standard administration of cisplatin included hydration, di-
uresis, and an antiemetic regimen. In addition to prespecified
dose reductions for cytopenias, a creatinine of 1.6 or greater
or a creatinine clearance of 50 ml/min or less warranted
reducing or holding the cisplatin dose, whereas hyperbiliru-
binemia mandated dose reductions of vinorelbine.
Response and toxicity for S9308 were measured ac-
cording to standard SWOG criteria.24 Patients remained on
study until progression of disease, unacceptable toxicity de-
termined by the treating physician and the study coordinator,
a delay in treatment of more than 4 weeks, institution of
palliative radiation, or patient refusal.
In S9509, patients were randomized to CP or CV. CV
were given in the same dose and schedule as in S9308:
cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2
weekly. Paclitaxel was given at 225 mg/m2 with carboplatin
given at an area under the curve of 6 every 3 weeks. Standard
administration of cisplatin was used with appropriate hydra-
tion, diuresis, and antiemetics. Prophylaxis against hypersen-
sitivity to paclitaxel administration was also given using
dexamethasone, antihistamines, and H2 blockers. Dose ad-
justments were made for hematologic toxicity, decline in
renal function, or neurotoxicity.
Standard SWOG criteria were used to determine re-
sponse in S9509, and toxicity was graded according to the
National Cancer Institute common toxicity criteria version
2.0.25 Patients remained on study until progression of disease,
unacceptable toxicity as determined by the treating physician
and the study coordinator, a delay in treatment of more than
2 weeks, need for palliative radiation, or patient refusal. In
the absence of progressive disease or unacceptable toxicity,
patients were treated with a minimum of six cycles or two
cycles past best response to a maximum of 10 cycles.
Statistical Methods
Fisher’s exact test was used for comparisons between
categorical variables (patient characteristics, response, and
adverse events). Comparisons between continuous variables
were performed using the Wilcoxon rank-sum or t test. Survival
estimates were calculated using the method of Kaplan-Meier.26
Confidence intervals for the median were calculated using the
method of Brookmeyer and Crowley.27 The differences between
survival curves were compared using the log-rank test. The
difference between Kaplan-Meier point estimates were per-
formed with a t test using standard errors based on Greenwood’s
formula. To adjust for multiple comparisons, permutation tests
were performed (with 1000 permutations).
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RESULTS
Patient Characteristics
A total of 616 patients who received combination
chemotherapy in trials S9308 and S9509 were eligible for this
analysis. For the purposes of analysis, patients treated with
CV were pooled from S9308 and S9509 (Figure 1). Of the
616 patients, 122 (20%) were aged 70 years or older, includ-
ing six patients aged 80 years or older. The median age was
63 years for patients enrolled on S9308 and 62 years for
patients enrolled on S9509. The proportion of patients who
were elderly was similar in each chemotherapy regimen with
39 patients aged 70 years or older treated with CP (19%) and
83 patients treated with CV (20%).
Table 1 lists the patient characteristics broken down by
age category (70 years and 70 years). Most patients had
stage IV disease with a smaller proportion of patients with
stage IIIB disease. There were slightly fewer patients in the
younger age group with stage IIIB disease, but this was not
statistically significant (p  0.18). The proportion of patients
with performance status of 0 or 1 was similar in both age
groups, as was weight loss (defined as greater or less than 5%
during the 6 months before study enrollment). The majority
of patients (82%) were white, and males constituted approx-
imately two thirds of all patients with similar percentages in
both groups. A small proportion in each group had received
prior radiation or surgery.
Efficacy
Response rates (Table 2) were similar in each age
category with approximately one quarter of patients experi-
encing an objective response. Nearly all responses were
partial. The remainder of patients had either stable or pro-
gressive disease. The estimated median progression-free sur-
vival (PFS) (Figure 2) was 4 months in both age groups (p 
0.71). Overall survival (OS) is displayed in Figure 3 by age
groups (Figure 3A) and by age groups according to treatment
(Figure 3B). Median OS estimates were 9 months and 7
months in the 70 years and 70 years age groups, respec-
tively (p  0.04). The proportion of patients surviving at 1
year was 40% in the group less than 70 years compared with
27% in patients aged 70 years or older (p  0.01). Two-year
survival was 16% and 10% in the younger and older cohorts,
respectively (p  0.07). The specific chemotherapy regimen
did not impact OS or PFS in either age group. A Cox
regression analysis adjusting for treatment arm, stage, perfor-
mance status, and weight loss was unable to detect an asso-
ciation between age and PFS with a p value of 0.89 but was
significant for an association with OS with a p value of 0.05.
Treatment Delivery
The median number of chemotherapy cycles completed
for patients younger than 70 years was 4 (interquartile range:
2–6 cycles), whereas patients aged 70 years or older com-
pleted a median of three cycles (interquartile range: 2–5
cycles), but the difference was not statistically significant
(p 0.06). There was a significant difference in the subset of
patients who received CV with patients aged 70 years or older
receiving a median of two cycles of therapy compared with
patients younger than 70 years who received a median of
three cycles (p  0.01 and remained significant when ad-
justed for multiple comparisons). There was no significant
difference between age groups in the subset of patients
treated with CP with patients aged 70 years or older receiving
a median of four cycles and those younger than 70 years
receiving a median of five cycles (p  0.7). The most
common reason for discontinuing treatment in the younger
cohort was disease progression, with 41% of patients younger
than 70 years stopping treatment for that reason. In patients
aged 70 years or older, toxicity was the most common reason
for treatment discontinuation, being noted in 36% of patients.
Toxicity
All patients included in the efficacy analysis were
included in the toxicity analysis (Table 3) except for nineFIGURE 1. Patient groups by treatment.
TABLE 1. Baseline Patient Characteristics
Age <70 yr Age >70 yr Total
Sex
Male 341 (69%) 80 (66%) 421 (68%)
Female 153 (31%) 42 (34%) 195 (32%)
Race
Black 80 (16%) 8 (7%) 88 (14%)
White 393 (80%) 111 (91%) 504 (82%)
Other/unknown/not reported 21 (4%) 3 (2%) 24 (4%)
Performance statusa
0 179 (37%) 39 (33%) 218 (36%)
1 310 (63%) 79 (67%) 389 (64%)
Weight lossb
5% 260 (54%) 66 (56%) 326 (55%)
5% 220 (46%) 52 (44%) 272 (45%)
Stagec
IIIB 47 (10%) 17 (14%) 64 (10%)
IV 447 (90%) 105 (86%) 552 (90%)
Prior treatment
Radiation 74 (15%) 18 (15%) 92 (15%)
Surgery 111 (23%) 25 (21%) 136 (22%)
Not reported 150 (30%) 38 (31%) 188 (31%)
a Of 607 evaluable patients, not statistically different (p  0.52).
b Of 598 evaluable patients, not statistically different (p  0.76).
c Of 616 evaluable patients, not statistically different (p  0.18).
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patients: seven in the CV group and two in the CP group.
Hematologic toxicity was similar in both groups. Notably,
76% and 83% of patients in the group less than 70 years and
the group  70 years, respectively, experienced grades 3 to 5
hematologic toxicity. Neutropenia represented the largest
percentage of grades 3 to 5 toxicity in each group although
rates of infection were much lower. Similarly, the groups did
not differ significantly in terms of nonhematologic toxicity
with rates of grades 3 to 5 toxicity of 53% in the less than 70
years group and 57% in the 70 years group, respectively.
Neuropathy was common, although for the majority of pa-
tients in both groups, it was grades 1 to 2. Of note, a larger
proportion of patients in the older age group experienced a
maximum toxicity of grades 3 to 5 (94%) compared with the
younger age group (87%), but this difference was not statis-
tically significant when adjusted for multiple comparisons. In
addition, there was no difference in toxicity between the
group less than 70 years and the group 70 years when each
chemotherapy regimen (CV or CP) was analyzed separately.
Among patients younger than 70 years and patients aged 70
years or older, there was a greater incidence of grade 3 or
worse neuropathy among patients receiving CP compared
with CV (p  0.001 for both comparisons). In addition,
among patients younger than 70 years, there was a higher
incidence of grade 3 or greater hematologic toxicity in the CV
arm (p  0.001). The remainder of measured toxicity param-
eters was not significantly different between the two chemo-
therapy groups. There were 16 (3%) treatment-related deaths
in the group less than 70 years and 5 (4%) in the group 70
years (p  0.64).
TABLE 2. Response Rates by Age
Age <70 yr (N  494) Age >70 yr (N  122)
pNo. Percentage 95% CI No. Percentage 95% CI
Overall response
(PR  CR)
131 27 23–31% 36 30 22–38% 0.51
Complete 5 1 1 1
Partial 126 26 35 29
No response 363 73 86 70
Stable disease 146 30 35 29
Progressive disease 140 28 27 22
Not assessable 77 16 24 20
PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response.
FIGURE 2. Progression-free survival (PFS) by age and
treatment.
FIGURE 3. A, Overall survival (OS) by age. B, Overall sur-
vival by age and treatment cisplatin/vinorelbine (CDDP/Vin);
carboplatin/paclitaxel (Carbo/Pac).
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DISCUSSION
In this retrospective analysis, patients aged 70 years or
older with advanced NSCLC treated with platinum-based
doublet therapy achieved comparable short-term benefit to
younger patients, but OS was worse in the older cohort.
Although PFS and response rates were similar in the two
groups, OS was significantly worse for patients aged 70 years
or older. A Cox regression analysis that adjusted for treat-
ment arm, stage, performance status, and weight loss showed
a similar result. No information is available regarding sec-
ond-line treatment in either patient group, which could cer-
tainly influence longer term outcomes. It is possible that older
patients may receive second-line chemotherapy less fre-
quently than their younger counterparts, which may explain
some of the difference in OS. There is a tendency toward
increased comorbidities in elderly patients with NSCLC,9
which may result in an inherently inferior survival unrelated
to the underlying malignancy in older compared with younger
patients. This concept cannot be analyzed in our study as no
baseline comorbidity data were recorded.
Toxicity is a major concern for older patients with
advanced NSCLC and their treating physicians. Elderly pa-
tients treated with CV received fewer cycles of chemotherapy
than their younger counterparts, whereas there was no statis-
tically significant difference in treatment delivery by age in
those patients treated with CP. Nevertheless, there was no
difference in toxicity according to age in patients treated with
either CV or CP. Despite significant neutropenia in both
groups, the rates of infection and neutropenic fever were low.
In addition, only a small percentage of neuropathy was
classified as grades 3 to 5 in either group. Of note, an
increased percentage of older patients experienced a maxi-
mum grade of any toxicity in the 3 to 5 range, although this
was not statistically significant. Our analysis along with prior
observations suggest that close observation and prudent dose
adjustments are warranted in elderly patients with NSCLC
receiving chemotherapy.13,18
One advantage to this type of analysis is the ability to
gather data on a larger group of elderly patients with NSCLC
by pooling data from two different SWOG trials. In addition,
cisplatin and carboplatin-based regimens remain the standard
backbone of therapy for advanced NSCLC, making this analysis
relevant to current patient care. Nevertheless, the analysis is
limited by its retrospective nature. In addition, the elderly pa-
tients participating in these two clinical trials may represent a
select group of older patients that both fit the inclusion criteria of
a performance status of 0 to 1 and were felt to be candidates for
a clinical trial by their treating physician and may not be
representative of the general population.
In this era of targeted therapies, new issues are emerg-
ing as to the potential benefit and risks of targeted agents in
elderly patients with NSCLC. The ECOG 4599 trial28 showed
the benefit of adding bevacizumab to carboplatin and pacli-
taxel in patients with advanced NSCLC. A retrospective
analysis29 of patients older than 70 years participating in this
trial demonstrated increased grade 3 or above toxicity in
elderly patients compared with younger patients but without
an efficacy benefit in the elderly. Both our analysis and the
E4599 outcome-by-age report emphasize the need for in-
creased participation of elderly patients in clinical trials and
elderly specific trials where feasible.
Although the treatment of NSCLC continues to evolve,
platinum-based doublet chemotherapy remains the standard
of care for patients with a favorable performance status. Our
analysis suggests that although patients older than 70 years
may derive comparable initial benefit from platinum-based
doublet therapy compared with younger patients, long-term
outcomes may not be as favorable. Given the inherent limi-
tations of retrospective analyses, only large-scale age-specific
prospective trials evaluating traditional therapies and newer
TABLE 3. Toxicity, Grades 3–5
Age <70 yr
(N  486) Percentage
Age >70 yr
(N  121) Percentage
Total
(N  607) Percentage p
Hematologic 367 76 100 83 467 77 0.12
Anemia 96 20 16 13 112 18 0.12
Thrombocytopenia 38 8 4 3 42 7 0.11
Neutropenia 340 70 95 79 435 72 0.07
Febrile neutropeniaa 4 1 1 1 5 1 1.00
Infection 64 13 15 12 79 13 0.88
Nonhematologic 260 53 69 57 329 54 0.54
Nausea 66 14 12 10 78 13 0.36
Vomiting 51 10 8 7 59 10 0.23
Diarrhea 16 3 1 1 17 3 0.22
Mucositis 6 1 0 0 6 1 0.60
Neuropathy 30 6 9 7 39 6 0.68
Fatigue 46 9 18 15 64 11 0.10
Maximum grade observed,
any toxicity (3–5)
424 87 114 94 538 89 0.04
Treatment-related deaths 16 3 5 4 21 3 0.64
a Febrile neutropenia data available only for S9509 (N  403).
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targeted agents will provide more definitive information on
appropriate therapeutic options for the rapidly growing cohort
of older patients with advanced NSCLC.
ACKNOWLEDGMENTS
Supported in part by the following PHS Cooperative
Agreement grant numbers awarded by the National Cancer
Institute, DHHS: CA32102, CA38926, CA-22433, CA-35431,
CA-58882, CA-04919, CA-46282, CA-37981, CA-20319,
CA-42777, CA-35090, CA-45807, CA-14028, CA-67663,
CA-35176, CA67575, CA-35281, CA-35261, CA-13612,
CA-27057, CA-46441, CA-76429, CA-76447, CA58415,
CA-35119, CA-58658, CA-58416, CA-35192, CA-45560,
CA-12644, CA-52654, CA-68183, CA-46368, CA-35178,
CA-74647, CA-58861, CA-35262, CA-28862, CA-58348,
CA-46136, CA-12213, CA-58686, CA-46113, CA45450,
CA-76448, CA-45377, CA-63845, CA-63850, CA-63844,
CA-52772, CA-45461, CA-16385, CA-35128, CA-76462,
CA-35117, CA-52651, CA-52650, CA-58723, and CA-35200.
REFERENCES
1. SEER Cancer Statistics Review 1875–2001. Available at: http://seer.
cancer.gov. Accessed February 10, 2009.
2. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends,
and multiple primary cancer analyses from the surveillance epidemiol-
ogy and end results (SEER) program. Oncologist 2007;12:20–37.
3. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and
improve quality of life in non-small-cell lung cancer: a review of the
literature and future directions. Clin Cancer Res 1998;4:1087–1100.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomized clinical trials. BMJ 1995;311:
899–909.
5. The NCCN Lung Cancer Clinical Practice Guidelines in Oncology
(Version v. 2. 2009). © 2006 National Comprehensive Cancer Network,
Inc. Available at: http://www.nccn.org. Accessed February 11, 2009.
6. Schiller JH, Harrington D, Belani C, et al. Comparison of four chemo-
therapy regimens for advanced non-small-cell lung cancer. New Engl
J Med 2002;346:92–98.
7. Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, out-
comes, and costs for older persons with advanced non–small-cell lung
cancer: evidence from Surveillance, Epidemiology and End Results—
Medicare. J Clin Oncol 2004;24:4971–4978.
8. Chrischilles E, Pendergast JF, Kahn KL, et al. Adverse events among the
elderly receiving chemotherapy for advanced non-small-cell lung can-
cer. J Clin Oncol 2009;28:620–627.
9. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly
patients: an analysis of the Surveillance, Epidemiology, and End Results
database. J Clin Oncol 2007;25:5570–5577.
10. Asmis TR, Ding K, Seymour L. Age and comorbidity as independent
prognostic factors in the treatment of non-small-cell lung cancer: a
review of National Cancer Institute of Canada Clinical Trials Group
trials. J Clin Oncol 2008;26:54–59.
11. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient
subgroups with unresectable non-small-cell lung cancer. Ann Oncol
2001;12:1671–1675.
12. O’Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic
importance of pretreatment clinical characteristics in patients with ad-
vanced non-small-cell lung cancer treated with combination chemother-
apy. J Clin Oncol 1986;4:1604–1614.
13. Rocha Lima CMS, Herndon JE, Kosty M, et al. Therapy choices among
older patients with lung carcinoma: an evaluation of two trials of the
Cancer and Leukemia Group B. Cancer 2002;84:181–187.
14. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of
vinorelbine on quality of life and survival of elderly patients with
advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66–72.
15. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients
with advanced non-small-cell lung cancer: the multicenter Italian lung
cancer in the elderly study (MILES) phase III randomized trial. J Natl
Can Inst 2003;95:362–372.
16. Lilenbaum RC, Herndon JE, List MA, et al. Single-agent versus com-
bination chemotherapy in advanced non-small-cell lung cancer: the
Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005;23:
190–196.
17. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from
second-line cytotoxic chemotherapy: a subset analysis of a randomized
phase III trial of pemetrexed compared with docetaxel in patients with
previously treated advanced non-small-cell lung cancer. J Clin Oncol
2006;24:4405–4411.
18. Langer CJ, Manola J, Bernado P, et al. Cisplatin-based therapy for
elderly patients with advanced non-small-cell lung cancer: implications
of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl
Cancer Inst 2002;94:173–181.
19. Kubota K, Furuse K, Kawahara M, et al. Cisplatin based combination
chemotherapy for elderly patients with non-small-cell lung cancer.
Cancer Chemother Pharmacol 1997;40:469–474.
20. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on
toxicity, response rate, quality of life, and survival in patients with
advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with
carboplatin and paclitaxel. Cancer 2003;98:779–788.
21. Langer CJ, Schiller J, Harrington DP, et al. Age-specific subanalysis of
ECOG 1594: fit elderly patients (70–80 YRS) with NSCLC do as well
as younger pts (70). Proc Am Soc Clin Oncol 2003:Abstract #2571.
22. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial com-
paring cisplatin with cisplatin plus vinorelbine in the treatment of
advanced non-small-cell lung cancer: a Southwest Oncology Group
Study. J Clin Oncol 1998;16:2459–2465.
23. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of
paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the
treatment of patients with advanced non-small-cell lung cancer: a South-
west Oncology Group Study. J Clin Oncol 2001;19:3210–3218.
24. Green S, Weiss GR. Southwest Oncology Group standard response
criteria, endpoint definitions and toxicity criteria. Invest New Drugs
1992;10:239–253.
25. National Cancer Institute: Common Toxicity Criteria (version 2). Be-
thesda, MD: Division of Cancer Treatment and Diagnosis, National
Cancer Institute, 1999. Available at: http://www.fda.gov/cder/cancer/
toxicityframe.htm. Accessed August 2009.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete obser-
vations. JASA 1958;53:457–481.
27. Brookmeyer R, Crowley J. A confidence interval for the median survival
time. Biometrics 1982;38:29–41.
28. Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;
355:2542–2550.
29. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly,
advanced-stage non-small-cell lung cancer patients treated with bevaci-
zumab in combination with carboplatin and paclitaxel: analysis of
Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;
26:60–65.
Blanchard et al. Journal of Thoracic Oncology • Volume 6, Number 1, January 2011
Copyright © 2010 by the International Association for the Study of Lung Cancer120
